ImmuCell CorpNASDAQ:ICCC
- LAST PRICE5.0400
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots4.2800/ 1
- Ask / Lots5.2000/ 1
- Open / Previous Close0.0000 / 5.0400
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ICCC |
|---|---|---|
| 11:29 ET | 1737 | 5.0591 |
| 01:10 ET | 500 | 5.02 |
| 01:12 ET | 148 | 5.02 |
| 01:21 ET | 200 | 5.02 |
| 01:30 ET | 131 | 5.02 |
| 01:57 ET | 100 | 5.03 |
| 02:13 ET | 100 | 5.04 |
| 03:09 ET | 199 | 5.03 |
| 03:36 ET | 200 | 5.02 |
| 03:39 ET | 100 | 5.02 |
| 03:45 ET | 539 | 5.02 |
| 03:52 ET | 300 | 5.03 |
| 03:56 ET | 111 | 5.03 |
| 03:59 ET | 100 | 5.04 |
Apr 9, 2024
ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024, from 4:05PM ET on Tuesday Apr 09, 2024 by Dow Jones
4:05PM ET on Tuesday Apr 09, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
ImmuCell Corp | 39.1M | -6.8x | --- |
Cara Therapeutics Inc | 36.7M | -0.3x | --- |
Aligos Therapeutics Inc | 62.7M | -0.5x | --- |
Viaderma Inc | 11.5M | 0.0x | --- |
Celularity Inc | 73.6M | -0.3x | --- |
Emmaus Life Sciences Inc | 5.4M | -1.1x | --- |
Company Information
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing Immediate Immunity against each of the three causes of calf scours (E. coli, coronavirus, and rotavirus).
Contact Information
- Headquarters
- 56 Evergreen DrivePORTLAND, ME, United States 04103
- Phone
- 207-878-2770
- Fax
- 302-655-5049
Executives
- Independent Non-Executive Chairman of the Board
- David Tomsche
- President, Chief Executive Officer, Treasurer, Secretary, Director
- Michael Brigham
- Vice President - Sales and Marketing, Director
- Bobbi Brockmann
- Vice President - Manufacturing Operations
- Elizabeth Williams
- Independent Director
- Gloria Basse
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $39.1M |
|---|---|
Revenue (TTM) | $17.5M |
Shares Outstanding | 7.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.60 |
EPS | $-0.75 |
Book Value | $3.22 |
P/E Ratio | -6.8x |
Price/Sales (TTM) | 2.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -30.81% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
